NCT05815901

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 588 (estimated)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.

Conditions

• Gout

Interventions

Type	Name	Description
DRUG	Epaminurad 6 mg	Epaminurad 6 mg tablet
DRUG	Epaminurad 9 mg	Epaminurad 9 mg tablet
DRUG	Febuxostat 40 mg	Febuxostat 40 mg tablet
DRUG	Febuxostat 80 mg	Febuxostat 80 mg tablet
DRUG	Epaminurad 6 mg placebo	Placebo tablet
DRUG	Epaminurad 9 mg placebo	Placebo tablet
DRUG	Febuxostat 40 mg placebo	Placebo tablet
DRUG	Febuxostat 80 mg placebo	Placebo tablet

Timeline

• Start date: 2023-03-21
• Primary completion: 2024-03-26
• Completion: 2026-04-17
• First posted: 2023-04-18
• Last updated: 2026-04-09

Locations

1 site across 1 country: South Korea